Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Company Overview

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. Utilizing its proprietary Targeted RNAi Molecule (TRiMTM) platform and advanced delivery systems, Arrowhead aims to silence disease-causing genes and address a broad range of unmet medical needs. The company’s pipeline spans multiple therapeutic areas including cardiovascular, metabolic, respiratory, renal, hepatic and infectious diseases.

Founded in 2008 and headquartered in Pasadena, California, Arrowhead has built a robust research and development organization with both in-house and collaborative efforts. Since its initial public offering in 2014 (NASDAQ: ARWR), the company has advanced several programs into clinical trials, including candidates targeting chronic hepatitis B, alpha-1 antitrypsin deficiency and hemophilia. Arrowhead’s scientific team has published extensively on mechanisms of RNAi and delivery strategies, contributing to a deeper understanding of gene silencing therapeutics.

Arrowhead maintains strategic partnerships and research collaborations with major pharmaceutical firms to enhance its development capabilities and accelerate clinical progress. These collaborations provide access to complementary expertise, specialized resources and expanded geographic reach. The company’s research sites are located across the United States, and its clinical trials also engage investigators and patients in Canada, Europe and Asia.

Under the leadership of Chief Executive Officer Christopher Anzalone and Chief Financial Officer Quentin Magee, Arrowhead continues to expand its pipeline and strengthen its technology platforms. The company is committed to rigorous clinical development, regulatory engagement and eventual commercialization of RNAi-based medicines that offer new treatment options for patients with serious diseases worldwide.

Key Stats

• Today's Range: $18.10 to $18.69
• 50-Day Range: $13.01 to $18.88
• 52-Week Range: $9.57 to $30.41
• Volume: 1.45 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $2.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.71
• Consensus Rating: Moderate Buy

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

Arrowhead Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 265th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arrowhead Pharmaceuticals is -13.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arrowhead Pharmaceuticals is -13.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Arrowhead Pharmaceuticals has a PEG Ratio of 21.53. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Arrowhead Pharmaceuticals has a P/B Ratio of 11.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.55% of the float of Arrowhead Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arrowhead Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.55

Percentage of Shares Shorted

9.55% of the float of Arrowhead Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.80

News Sentiment

Arrowhead Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Arrowhead Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.

Percentage Held by Institutions

62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARWR Stock Analysis - Frequently Asked Questions

How have ARWR shares performed this year?

Arrowhead Pharmaceuticals' stock was trading at $18.80 at the beginning of 2025. Since then, ARWR shares have decreased by 2.6% and is now trading at $18.31.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Monday, May, 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The biotechnology company earned $542.71 million during the quarter, compared to analyst estimates of $116.27 million.
Read the conference call transcript.

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.02%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener.
View institutional ownership trends.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARWR
• CIK: 879407
• Web: www.arrowheadpharma.com
• Phone: (626) 304-3400
• Fax: 626-304-3401
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Arrowhead Pharmaceuticals: $43.71
• High Price Target: $80.00
• Low Price Target: $17.00
• Potential Upside/Downside: +138.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 22.18
• Net Income: -$599.49 million
• Net Margins: N/A
• Pretax Margin: -27.93%
• Return on Equity: -45.33%
• Return on Assets: -12.49%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 5.15
• Quick Ratio: 5.15

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 712.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 11.89

Miscellaneous

• Outstanding Shares: 138,100,000
• Free Float: 132,162,000
• Market Cap: $2.53 billion
• Optionable: Optionable
• Beta: 0.93